Trial of Marimastat for Advanced Pancreatic Cancer

Sample size: 113 publication Evidence: moderate

Author Information

Author(s): Evans J D, Stark A, Johnson C D, Daniel F, Carmichael J, Buckels J, Imrie C W, Brown P, Neoptolemos J P

Primary Institution: Department of Surgery, Queen Elizabeth Hospital, Birmingham, UK

Can marimastat, a matrix metalloproteinase inhibitor, improve outcomes in patients with advanced pancreatic cancer?

Marimastat showed some potential benefits in stabilizing disease and improving pain management in patients with advanced pancreatic cancer.

Of 113 patients, 90 (80%) completed the 28-day study.
41 (49%) of 83 patients with assessable disease had stable disease.
The median survival was 245 days for those with stable or falling CA19-9 levels.

This study tested a new medicine called marimastat to see if it helps people with a tough kind of cancer, and some patients felt better.

This was a multicentre phase II clinical trial where patients received marimastat for 28 days.

The study had a relatively small sample size and was limited to a short treatment duration.

Patients with advanced pancreatic cancer, including various stages of the disease.

Access the complete publication on the publisher's website